Molecular Portrait of Integrin Beta-6 (IB6): Characterization of IB6 Expression and Co-Mutation Patterns From the U.S. Real-world Data Study

AMP 2025

Nov 11, 2025
Oncology
Presentation

M. Fidler, L. Clinton, L. Hsu, J. Smith, S. Whitman, B. Li, P. Cronin, R. Gennarelli, E. Davis, J. Berndt, A. Brackey, D. Jenkins, D. Bloch, S. Bell, L. Walls, J. Borgia

Introduction
IB6, encoded by ITGB6, is highly expressed in several solid

 

tumors, including non-small-cell lung cancer (NSCLC), and is a promising

 

therapeutic target. The investigational IB6-directed antibody-drug

 

conjugate sigvotatug vedotin has shown encouraging activity in NSCLC

 

(Peters, ASCO 2024). Here are preliminary results from the IB6

 

Expression and Clinical Outcomes in NSCLC study, which was conducted

 

to characterize real-world IB6 expression and its clinical relevance, and

 

investigate potential association with established or exploratory

 

biomarkers in patients with metastatic NSCLC (mNSCLC). Methods: This

 

retrospective, real-world, observational study used the Tempus deidentified patient record database to examine data for US patients with

 

mNSCLC who had tumor sequencing data available after May 2019.

 

Patient demographics and clinical characteristics were obtained via

 

electronic health record integration and clinical record abstraction. Tissue

 

samples from primary or metastatic lesions underwent IB6

 

immunohistochemistry (IHC) and were manually scored by a pathologist

 

to characterize IB6 as high or low using a pre-specified method. The study

 

objectives included characterization of real-world IB6 expression by IHC

 

and exploration of the correlation between IB6 expression by IHC and

 

RNA level and association with other relevant NSCLC biomarkers,

 

including PD-L1, EGFR, ALK, KRAS, TACSTD2 (alias TROP2), and

 

cMET. Results: In the preliminary cohort of 129 patients, median age was

 

66 years; 52.7% were female, 47.3% were White, and 35.7% were Black

 

or African American. Of the tissue samples, 37.2% were from primary

 

tumors, and 68.2% had non-squamous histology. Prevalence of high IB6

 

expression in the 117 evaluable mNSCLC tumor samples was 70.9%. IB6

 

expression varied by histology, with high IB6 expression in 76.9% of nonsquamous and 42.1% of squamous samples. Median ITGB6 RNA

 

expression was significantly higher in the IB6-high versus -low cohort (6.3

 

log2[TPM+1] versus 3.7 log2[TPM+1]; P <0.001). Due to limited sample

 

size, the association of IB6 with PD-L1, TACSTD2, and cMET was

 

evaluated. Prevalence of PD-L1 expression (defined as tumor proportion

 

score ≥1%) was similar in the IB6-high and -low subgroups (65.1% versus

 

55.9%). Median RNA expression of TACSTD2 and cMET did not

 

significantly differ by IB6 expression status. Conclusions: In this sample

 

of diverse US patients with mNSCLC, high IB6 expression was common,

 

particularly in non-squamous histology, underscoring the potential of IB6

 

as a novel therapeutic target. Initial results support a correlation between

 

IB6 expression by IHC and RNA sequencing. No notable trend was

 

observed between IB6 expression status and PD-L1, TACSTD2, or cMET

 

expression. Further investigation of IB6-directed therapies is warranted.